Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD
BURLINGTON, ON, February 15, 2022 – Boehringer Ingelheim (Canada) Ltd. and the pan-Canadian Pharmaceutical Alliance (pCPA) have completed negotiations for OFEV® (nintedanib), a multi-targeted tyrosine kinase inhibitor for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as PF-ILD).1
OPSYNVI® (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)
TORONTO, Oct. 15, 2021 /CNW/ – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada approved OPSYNVI® (macitentan 10mg and tadalafil 40mg) for the long-term treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to reduce morbidity in patients of WHO functional class (FC) II or III whose PAH is idiopathic, heritable, or associated with connective tissue disease or congenital heart disease.
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
BURLINGTON, ON, March 4, 2021 /CNW/ – Boehringer Ingelheim (Canada) Ltd. is pleased to announce positive recommendations from the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d’excellence en santé et services sociaux (INESSS) for OFEV® (nintedanib) for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype (also known as PF-ILD) when certain conditions are met.